The Effect of Lixisenatide on the Effect of Pituitary Hormones

NCT05804513 · Unknown status

Last updated 2026-05-28

This clinical trial tested the effect of the medication lixisenatide on pituitary hormones in healthy individuals and people with Type 1 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind diagnostic study

Participants 10 people Planned (estimated).

Who can join Ages 18–60 · male only Healthy volunteers accepted.

Timeline Started 2023-04 · est. completion 2023-12

Where 1 site · Estonia

What this study is testing ClinicalTrials.gov NCT05804513 ↗

Description as written by the study sponsor.

The current study has two aims: 1. to test the hypothesis that a single dose of lixisenatide can be used as a growth hormone stimulation test; 2. to test if the growth hormone-stimulating effect is mediated by changes in blood glucose. The secondary objective of the study is to monitor the effect of lixisenatide on other pituitary hormones and physiological parameters (blood glucose, blood pressure, heart rate, nausea).

Treatments tested

Placebo also known as Sodium chloride 0.9% solution Drug

s/c injection
Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector also known as Lyxumia Drug

s/c injection

Main thing measured	Growth hormone area under the curve.
Sponsor	University of Tartu
Conditions studied	Healthy, Type 1 Diabetes
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05804513 ↗